血脂康对高血压病患者血浆sICAM-1水平和PAI-1活性的影响

Effects of xuezhikang on plasma levels of sICAM-1 and PAI-1 in patients with essential hypertension

目的 探讨高血压病 (EH)患者血浆细胞间粘附分子 - 1(sICAM - 1)水平和纤溶酶原激活物抑制剂 - 1(PAI -1)活性的变化及血脂康对其的影响。方法 采用酶联免疫吸附法 (ELISA)、发色底物显色法分别对 71例轻至中度高血压患者应用血脂康治疗前后和正常对照组者血浆sICAM - 1水平和PAI- 1活性进行检测。结果 EH患者血浆sICAM - 1水平和PAI- 1活性明显高于正常对照组 (P <0 .0 1及P <0 .0 5 ) ,经血脂康治疗 8周后其浓度明显下降(P <0 .0 1及P <0 .0 5 )。结论 EH病人血浆sICAM - 1水平和PAI- 1活性较正常人明显升高 ,血脂康在有效调脂的同时能降低EH患者血sICAM - 1浓度和PAI- 1活性 ,减少高血压并发症发生。

Objective To investigate the level of plasma soluble intercellular adhesion molecule-1(sICAM-1),activity of plasminogen activiator inhibitor-1(PAI-1) and the effects of xuezhikang in patients with essential hypertension(EH).Methods Enzyme linked immunosorbent assay(ELISA),spectrophotmetric assay were used to measure the plasma level of sICAM-1,activity of PAI-1 in 71 patients with mild to moderate essential hypertension before and after xuezhikang treatment and 30 normotensive controls.Results Hypertensive patients exhibited significantly higher level of sICAM-1 and higher activity of PAI-1 than did normotensive controls(P<0.01 and P<0.05) . The level of plasma sICAM-1 and activity of PAI-1 in hypertensives were significantly decreased after 8 weeks of xuezhikang treatment(P<0.01 and P<0.05).Conclusion Plasma level of sICAM-1 and activity of PAI-1 are elevated in hypertensive patients.Xuezhikang not only decreased TC,TG and LDL, but also decreased level of sICAM-1 and activity of PAI-1.